Prchal-Murphy Michaela, Witalisz-Siepracka Agnieszka, Bednarik Karoline T, Putz Eva Maria, Gotthardt Dagmar, Meissl Katrin, Sexl Veronika, Müller Mathias, Strobl Birgit
Institute of Animal Breeding and Genetics; University of Veterinary Medicine ; Vienna, Austria ; Institute of Pharmacology and Toxicology; University of Veterinary Medicine ; Vienna, Austria.
Institute of Animal Breeding and Genetics; University of Veterinary Medicine ; Vienna, Austria.
Oncoimmunology. 2015 May 26;4(11):e1047579. doi: 10.1080/2162402X.2015.1047579. eCollection 2015 Nov.
Tyrosine kinase 2 (TYK2) is a Janus kinase (JAK) that is crucially involved in inflammation, carcinogenesis and defense against infection. The cytotoxic activity of natural killer (NK) cells in TYK2-deficient () mice is severely reduced, although the underlying mechanisms are largely unknown. Using mice and mice expressing a kinase-inactive version of TYK2 ( ), we show that NK cell function is partly independent of the enzymatic activity of TYK2. and NK cells develop normally in the bone marrow, but the maturation of splenic NK cells (and to a lesser extent of NK cells) is impaired. In contrast, the production of interferon γ (IFNγ) in response to interleukin 12 (IL-12) or to stimulation through NK cell-activating receptors strictly depends on the presence of enzymatically active TYK2. The cytotoxic activity of NK cells against a range of target cells is higher than that of NK cells. Consistently, mice control the growth of NK cell-targeted tumors significantly better than TYK2-deficient mice, showing the physiological relevance of the finding. Inhibitors of TYK2's kinase activity are being developed for the treatment of inflammatory diseases and cancers, but their effects on tumor immune surveillance have not been investigated. Our finding that TYK2 has kinase-independent functions suggests that such inhibitors will leave NK cell mediated tumor surveillance largely intact and that they will be suitable for use in cancer therapy.
酪氨酸激酶2(TYK2)是一种 Janus 激酶(JAK),在炎症、致癌作用及抗感染防御中起关键作用。尽管其潜在机制大多未知,但在缺乏TYK2的小鼠中,自然杀伤(NK)细胞的细胞毒性活性严重降低。利用基因敲除小鼠和表达激酶失活型TYK2的小鼠,我们发现NK细胞功能部分独立于TYK2的酶活性。基因敲除小鼠和激酶失活型小鼠的NK细胞在骨髓中正常发育,但脾脏中基因敲除小鼠NK细胞(以及程度较轻的激酶失活型小鼠NK细胞)的成熟受到损害。相比之下,对白细胞介素12(IL-12)或通过NK细胞激活受体刺激产生的干扰素γ(IFNγ)严格依赖于具有酶活性的TYK2的存在。基因敲除小鼠的NK细胞对一系列靶细胞的细胞毒性活性高于激酶失活型小鼠的NK细胞。同样,基因敲除小鼠对NK细胞靶向肿瘤生长的控制明显优于TYK2缺陷小鼠,表明了这一发现的生理相关性。正在开发TYK2激酶活性抑制剂用于治疗炎症性疾病和癌症,但尚未研究它们对肿瘤免疫监视的影响。我们发现TYK2具有不依赖激酶的功能,这表明此类抑制剂将在很大程度上保持NK细胞介导的肿瘤监视功能,并且它们将适用于癌症治疗。